Galectin Therapeutics (GALT) Tops Q3 EPS by 5c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• TE Connectivity (TEL) call put ratio 1.6 calls to 1 put as share price down 2%
• Venezuela oil export revenue rises 21.5% in first quarter